Vedolizumab Activity in Different Stage of Crohn’s Disease
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on April 22nd, 2026
|
Crohn’s disease is a chronic autoimmune condition in which dysregulated immune activity leads to inflammation and structural damage of the intestinal wall. Vedolizumab, a gut-selective biologic therapy, has already been approved for its management. A recent study published in the Lancet examined whether the timing of vedolizumab initiation - early versus late in the disease course - affects treatment outcomes.
Funding Source(s): Takeda Nederland
This phase 4 trial was conducted in Hungary, the Netherlands, and Belgium, and included 260 patients with moderately to severely active Crohn’s disease. Disease severity was assessed using the Crohn’s Disease Activity Index, with a median baseline score of 255. Participants were categorized into early-stage disease (diagnosed within the past two years) and late-stage disease. Only patients in the late-stage group had prior exposure to anti-TNF therapy, with over 70% having been treated with infliximab or adalimumab.
All participants received intravenous vedolizumab at a dose of 300 mg every eight weeks. Vedolizumab is a monoclonal antibody that targets the α4β7 integrin on gut-homing lymphocytes, blocking its interaction with mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1). This prevents immune cells from migrating into intestinal tissue, thereby reducing localized inflammation.
After 52 weeks of treatment, patients in the early disease group showed significantly better outcomes. Endoscopic assessment revealed resolution of ulceration in 47.7% of early-stage patients, compared with 23% in the late-stage group. Mucosal healing was also more frequent in the early group (57%) than in the late group (35.6%). Additionally, patients with long-standing disease reported higher rates of adverse events, including fatigue, headache, respiratory infections, and skin-related issues. These findings suggest that earlier initiation of vedolizumab may lead to improved disease control and better clinical outcomes in patients with Crohn’s disease.
Funding Source(s): Takeda Nederland
This phase 4 trial was conducted in Hungary, the Netherlands, and Belgium, and included 260 patients with moderately to severely active Crohn’s disease. Disease severity was assessed using the Crohn’s Disease Activity Index, with a median baseline score of 255. Participants were categorized into early-stage disease (diagnosed within the past two years) and late-stage disease. Only patients in the late-stage group had prior exposure to anti-TNF therapy, with over 70% having been treated with infliximab or adalimumab.
All participants received intravenous vedolizumab at a dose of 300 mg every eight weeks. Vedolizumab is a monoclonal antibody that targets the α4β7 integrin on gut-homing lymphocytes, blocking its interaction with mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1). This prevents immune cells from migrating into intestinal tissue, thereby reducing localized inflammation.
After 52 weeks of treatment, patients in the early disease group showed significantly better outcomes. Endoscopic assessment revealed resolution of ulceration in 47.7% of early-stage patients, compared with 23% in the late-stage group. Mucosal healing was also more frequent in the early group (57%) than in the late group (35.6%). Additionally, patients with long-standing disease reported higher rates of adverse events, including fatigue, headache, respiratory infections, and skin-related issues. These findings suggest that earlier initiation of vedolizumab may lead to improved disease control and better clinical outcomes in patients with Crohn’s disease.